Guo Kai, Qiu Ming-Xing, Cai Song-Liang, Leng Jing, Han Yin-Fa, Shao Guo-Xing, Wang Chuan-Hang, Tu Xiang-An, Yang Luo-Yan, Chen Ge-Ming, Zhou Qiang, Deng Yong, Wang Xiao-Long
Department of Urology, Peopleś Hospital of Sichuan Province, Chengdu, Sichuan 610072, China.
Zhonghua Nan Ke Xue. 2007 Oct;13(10):950-2.
To observe the efficacy and safety of Qianlieantong Tablets in the treatment of chronic prostatitis.
A multi-center, self-controlled open clinical trial was conducted. A total of 280 subjects with chronic prostatitis were enrolled and treated by Qianlieantong Tablets, 3 times a day, 5 tablets each time. Before and after 2 and 4 weeks after the administration, NIH-CPSI scores and white blood cell counts in the prostate secretion were recorded.
Of the 273 subjects evaluated, the rates of excellence, effectiveness and ineffectiveness were 35.2% (n = 96), 47.6% (n = 130) and 17.2% (n = 47), respectively, with a total effectiveness rate of 82.8%. After 4 weeks'medication, the scores of the subjects on NIH-CPSI pain, voiding and quality of life and white blood cell counts in prostate secretion were significantly decreased compared with pre-treatment (P < 0.01). No adverse events or laboratory abnormality related to the medication were observed.
Qianlieantong Tablets has a significant effect on chronic prostatitis with high safety, particularly indicated in chronic prostatitis with pelvic pain.
Zotero 插件